✦ Oct. 8: The FDA approved Clinuvel Pharmaceuticals Ltd.’s Scenesse (afamelanotide) for the treatment of adults who have a history of phototoxic reactions from erythropoietic protoporphyria. The agency says the implant is the first approved treatment to increase these patients’ light exposure. It had priority review and orphan drug designation. One implant is injected subcutaneously by a physician every two months during the spring and summer months, with a recommended three implants per year and no more than four. The company said it would not price the drug above its European price, which ranges from $76,811 to $109,730 per patient per year, reported Reuters. Visit https://bit.ly/2okzbwQ.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.